Irritable Bowel Syndrome (IBS) Treatment Market To Reach $20.5 Billion by 2035

Irritable bowel syndrome (IBS) treatment market is projected to grow from $12.4 billion in 2025 to $20.5 billion by 2035, expanding at a CAGR of 5.2% during the forecast period. The market growth is driven by the increasing global burden of gastrointestinal disorders, rising awareness of functional bowel diseases, and continuous innovation in targeted therapies. A key macro driver supporting this growth is the rising prevalence of digestive disorders worldwide. According to the World Health Organization (WHO), gastrointestinal diseases impact a substantial share of the global population, with functional disorders such as IBS affecting approximately 10–15% of adults globally. Additionally, healthcare utilization trends indicate increasing diagnosis rates. Data from the Organisation for Economic Co-operation and Development (OECD) shows that healthcare spending across member nations accounts for nearly 9–12% of GDP, highlighting strong investments in chronic disease management, including gastrointestinal conditions. These trends are directly increasing demand for pharmacological IBS treatments across hospitals, specialty clinics, and homecare settings.

Browse the full report description of “Irritable Bowel Syndrome (IBS) Treatment Market Size, Share & Trends Analysis Report, By IBS Type (IBS-C, IBS-D, IBS-M, IBS-U), By Drug Class (Laxatives, Antidiarrheal Agents, Antispasmodics, Antibiotics, Serotonin Receptor Modulators, GC-C Agonists, Chloride Channel Activators, Antidepressants, Bile Acid Sequestrants), By End User (Hospitals, Specialty Gastroenterology Clinics, Homecare Settings), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/irritable-bowel-syndrome-ibs-treatment-market

Among drug classes, Guanylate Cyclase-C (GC-C) agonists are emerging as the fastest-growing segment due to their targeted mechanism of action and superior efficacy in managing IBS-C symptoms. These therapies are witnessing strong adoption in developed markets due to improved clinical outcomes compared to conventional laxatives and antispasmodics.

• In November 2025, the U.S. Food and Drug Administration approved Linzess (linaclotide) capsules for pediatric patients aged 7 years and older with irritable bowel syndrome with constipation (IBS-C), marking the first FDA-approved treatment for this condition in children and expanding the scope of IBS therapeutics into the pediatric population.
• In January 2025, Amneal Pharmaceuticals received tentative approval from the U.S. Food and Drug Administration for rifaximin 550 mg tablets, referencing XIFAXAN, for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults, indicating potential future market entry of a generic alternative subject to ongoing litigation.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By IBS Type
  • By Drug Class
  • By End users
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape – AbbVie Inc, Ironwood pharmaceuticals, Takeda Pharmaceutical Company, Bausch Health companies Inc, Allergan, among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Irritable Bowel Syndrome (IBS) Treatment Market Report Segment

By IBS Type

• IBS with Constipation (IBS-C)
• IBS with Diarrhea (IBS-D)
• Mixed IBS (IBS-M)
• Unsubtyped IBS (IBS-U)

By Drug Class

• Laxatives
• Antidiarrheal Agents
• Antispasmodics
• Antibiotics
• Serotonin Receptor Modulators
• Guanylate Cyclase-C Agonists
• Chloride Channel Activators
• Antidepressants
• Bile Acid Sequestrants

By End User

• Hospitals
• Specialty Gastroenterology Clinics
• Homecare Settings

Global Irritable Bowel Syndrome (IBS) Treatment Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/irritable-bowel-syndrome-ibs-treatment-market